DelveInsight's Mismatch Repair Deficiency Market Insights report includes a comprehensive understanding of current treatment practices, mismatch repair deficiency emerging drugs, market share of ...
Patients with mismatch repair deficient gastric cancer demonstrated better median overall survival when skipping perioperative chemotherapy, according to a preprint study. Median overall survival is ...
The latest update is out from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ). Sihuan Pharmaceutical Holdings Group Ltd. announced that its ...
MSD and Eisai presented the data at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The ...
NG-350A has received FDA fast track designation for mismatch repair-proficient locally advanced rectal cancer, addressing a ...
Dr. Praveen Vikas, Dr. Tyler Johnson, and Dr. Russell Broaddus present the ASCO endorsement of the Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ...
The new CAP guideline published in August 2022 recommends using immunohistochemistry (IHC) to test for mismatch repair defects in gastroesophageal (GE), small bowel (SB), or endometrial carcinoma (EC) ...
MedPage Today on MSN
Chemotherapy-Free Combo Improves Survival in Metastatic Colorectal Cancer
BERLIN -- The investigational tyrosine kinase inhibitor (TKI) zanzalintinib plus atezolizumab (Tecentriq) significantly ...
Results showed a DFS benefit with the addition of pembrolizumab to chemotherapy for patients with mismatch repair-deficient tumors. The rate of grade 3 or greater adverse events was slightly higher ...
Xuanzhu Biopharmaceutical Co., Ltd. Class H ( ($HK:2575) ) just unveiled an update. Xuanzhu Biopharmaceutical Co., Ltd. announced that its product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback